IP Library › Granted Patent US 10,662,235
Granted Patent B2
US 10,662,235 · App. 15/629,090 · Granted May 26, 2020

Cysteine engineered fibronectin type III domain binding molecules

Inventors: Mark Anderson (Eagleville, PA); Ricardo Attar (Lawrence Township, PA); Michael Diem (Havertown, PA); Linus Hyun (King of Prussia, PA); Alastair King (Lake Saint Louis, MO); Steven Jacobs (North Wales, PA); Shalom Goldberg (Merion Station, PA); Donna Klein (Philadelphia, PA); Sheri Moores (Wayne, PA); Karyn O'Neil (Media, PA); Kristen Picha (Malvern, PA)
Assignee: Janssen Biotech, Inc.
C07K14/78C07K14/71C07K19/00C12N15/09C12N15/63C12N15/64C07K2319/00C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,662,235
App. No.
15/629,090
Granted
May 26, 2020
Kind
B2
Abstract

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Claims (15)

1. A protein comprising an amino acid sequence of any one of SEQ ID NOS: 266-273, wherein the protein has at least one cysteine substitution at a position that corresponds to a position selected from the group consisting of residues 6, 8, 10, 11, 14, 15, 16, 20, 30, 34, 38, 40, 41, 45, 47, 48, 53, 54, 59, 60, 62, 64, 70, 88, 89, 90, 91, and 93 of the amino acid sequence of SEQ ID NO: 27.

2. The protein of claim 1 , wherein the protein is chemically-conjugated to a thiol-reactive reagent.

3. The protein of claim 2 , wherein the thiol-reactive reagent is a maleimide moiety.

4. The protein of claim 3 , wherein the maleimide moiety is selected from the group consisting of NEM, PEG24-maleimide, fluorescein maleimide, MMAE, and MMAF.

5. The protein of claim 1 , further comprising a half-life extending moiety.

6. The protein of claim 5 , wherein the half-life extending moiety is CD8 binding molecule, albumin, an albumin variant, an albumin binding molecule, a polyethylene glycol (PEG), CD8, CD8 variant, or at least a portion of an Fc region of an immunoglobulin.

7. The protein of claim 6 , wherein the albumin binding molecule is an albumin binding FN3 domain.

8. The protein of claim 1 , wherein the protein further comprises the amino acid sequence of SEQ ID NO:274.

9. A protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, and SEQ ID NO:273.

10. An isolated polynucleotide encoding the protein of claim 1 .

11. A vector comprising the polynucleotide of claim 10 .

12. An isolated host cell comprising the vector of claim 11 .

13. A method of producing the protein according to claim 1 , wherein a cell comprising a polynucleotide encoding the protein is cultured under conditions to produce the protein.

14. The method of claim 13 , further comprising introducing the polynucleotide encoding the protein into the cell prior to the culturing step.

15. The method of claim 13 , further comprising purifying the protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2020
From: ANDERSON, MARK; ATTAR, RICARDO; DIEM, MICHAEL; GOLDBERG, SHALOM; HYUN, LINUS; JACOBS, STEVEN; KING, ALASTAIR; KLEIN, DONNA; MOORES, SHERI; O'NEIL, KARYN; PICHA, KRISTEN
To: JANSSEN BIOTECH, INC.
Reel/Frame 052248/0013 →
Continuity (2)
Provisional Application 62352776 · Jun 21, 2016
Related Publication 20170362301A1 · Dec 21, 2017
Cited By (2)
US 12,351,619 US 12,599,652